Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $19.67.

TEVA has been the topic of a number of analyst reports. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Wednesday, July 10th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $18.78 on Wednesday. The company has a market cap of $21.27 billion, a PE ratio of -48.14, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries has a twelve month low of $8.55 and a twelve month high of $19.08. The company’s 50 day moving average is $18.03 and its 200 day moving average is $17.06. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. New Covenant Trust Company N.A. purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $28,000. EntryPoint Capital LLC purchased a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $30,000. UMB Bank n.a. lifted its holdings in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at $48,000. Finally, Byrne Asset Management LLC purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at $52,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.